{"id":967299,"date":"2026-05-27T07:33:59","date_gmt":"2026-05-27T11:33:59","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/jupiter-neurosciences-announces-patient-enrollment-underway-in-phase-2a-reset-trial-in-parkinsons-disease\/"},"modified":"2026-05-27T07:33:59","modified_gmt":"2026-05-27T11:33:59","slug":"jupiter-neurosciences-announces-patient-enrollment-underway-in-phase-2a-reset-trial-in-parkinsons-disease","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/jupiter-neurosciences-announces-patient-enrollment-underway-in-phase-2a-reset-trial-in-parkinsons-disease\/","title":{"rendered":"Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson\u2019s Disease"},"content":{"rendered":"
\n

\n Investigational Oral Candidate JOTROL<\/i>
\n
\n \u2122<\/i>
\n <\/sup>
\n Addresses a Parkinson\u2019s Disease Market with No Current Disease-modifying Therapies Available<\/i>\n <\/p>\n

\n Jupiter, FL, May 27, 2026 (GLOBE NEWSWIRE) — <\/strong>Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage biopharmaceutical company developing investigational therapies for neurodegenerative diseases, today announced that patient enrollment is now underway in its Phase 2a RESET clinical trial (NCT07592767) for JOTROL\u2122<\/sup> (investigational trans-resveratrol micellar formulation) in Parkinson\u2019s Disease (PD), with first patient dosing expected in the near term.<\/p>\n

Parkinson\u2019s Disease affects an estimated 1.1 million people in the United States, with roughly 90,000 new diagnoses annually, and carries an estimated annual U.S. economic burden of $82.2 billion. The global PD treatment market was valued at $5.65 billion in 2024 and is projected to reach $7.58 billion by 2030, growing at a CAGR of about 5.0%. Despite decades of research, no disease-modifying therapies have been approved for PD to date. JOTROL\u2122 is an investigational drug candidate that has not been approved by the FDA or any regulatory authority. It is currently being evaluated for its potential to target underlying biological drivers of neurodegeneration.<\/p>\n

\n \u201cDespite advances in symptomatic management, there remains a significant unmet need for therapies that may address the underlying biological drivers of Parkinson\u2019s disease. We believe JOTROL<\/i>
\n
\n \u2122<\/i>
\n <\/sup>
\n \u2019s enhanced CNS exposure and mechanistic profile position it as a potentially differentiated therapeutic candidate for neurodegenerative disorders characterized by oxidative stress, mitochondrial dysfunction and chronic neuroinflammation.\u201d<\/i>\n <\/p>\n

\n \u2014 Charbel Moussa, MBBS, PhD<\/b>, Professor of Neurology and Director of the Translational Therapeutics Program, Georgetown University Medical Center; Coordinating Principal Investigator, RESET Study<\/p>\n

\n \u201cThe global Parkinson\u2019s Disease treatment market \u2014 currently valued at $5.65 billion and growing at a 5.04% CAGR \u2014 represents a significant and expanding unmet need that Jupiter Neurosciences is working to address with JOTROL<\/i>
\n
\n \u2122<\/i>
\n <\/sup>
\n . With enrollment now underway in the Phase 2a RESET trial we have reached a critical operational milestone. We look forward to generating the clinical data needed to evaluate JOTROL<\/i>
\n
\n \u2122<\/i>
\n <\/sup>
\n \u2019s potential and to serve patients, providers, and the broader scientific community.\u201d<\/i>\n <\/p>\n

\n \u2014 Christer Ros\u00e9n, Chief Executive Officer, <\/b>Jupiter Neurosciences, Inc.\u00a0(NASDAQ: JUNS)<\/b><\/p>\n

\n “The initiation of enrolment in the Phase 2a RESET trial marks the culmination of 10 years of research and development at Jupiter and is our largest clinical milestone to date. I echo the enthusiasm of my colleagues, thank all our collaborators contributing to this accomplishment and look forward to reporting out data as the trial progresses.\u201d <\/i>\n <\/p>\n

\n \u2014 Alison Silva, President & Chief Business Officer, <\/b>Jupiter Neurosciences, Inc.\u00a0(NASDAQ: JUNS)<\/p>\n

\n Clinical Trial Details<\/b>\n <\/p>\n

Jupiter\u2019s RESET (RESvEraTrol in Parkinson\u2019s Disease) is active on www.clinicaltrials.gov<\/a>, details here:<\/p>\n

\n Study Details | NCT07592767 | RESvEraTrol in Parkinson’s Disease (RESET) | ClinicalTrials.gov<\/a>. The trial is a multi-center, randomized, double-blind, placebo-controlled Phase 2a study designed to evaluate the JOTROL\u2122<\/sup> in Parkinson\u2019s Disease. In a well-established model of Parkinson\u2019s Disease JOTROL\u2122<\/sup> demonstrated statistically significant neuroprotective effects including rotarod performance and grip strength, indicating preservation of motor function. These data supported the IND granted to the Company in November 2025. A summary of key milestones and observations:<\/p>\n